1234 related articles for article (PubMed ID: 22182688)
21. Occurrence of neuronal inclusions combined with increased nigral expression of alpha-synuclein within dopaminergic neurons following treatment with amphetamine derivatives in mice.
Fornai F; Lenzi P; Ferrucci M; Lazzeri G; di Poggio AB; Natale G; Busceti CL; Biagioni F; Giusiani M; Ruggieri S; Paparelli A
Brain Res Bull; 2005 May; 65(5):405-13. PubMed ID: 15833595
[TBL] [Abstract][Full Text] [Related]
22. Nigrostriatal alpha-synucleinopathy induced by viral vector-mediated overexpression of human alpha-synuclein: a new primate model of Parkinson's disease.
Kirik D; Annett LE; Burger C; Muzyczka N; Mandel RJ; Björklund A
Proc Natl Acad Sci U S A; 2003 Mar; 100(5):2884-9. PubMed ID: 12601150
[TBL] [Abstract][Full Text] [Related]
23. Acetaminophen attenuates dopamine neuron degeneration in animal models of Parkinson's disease.
Locke CJ; Fox SA; Caldwell GA; Caldwell KA
Neurosci Lett; 2008 Jul; 439(2):129-33. PubMed ID: 18514411
[TBL] [Abstract][Full Text] [Related]
24. Impaired neurotransmission caused by overexpression of α-synuclein in nigral dopamine neurons.
Lundblad M; Decressac M; Mattsson B; Björklund A
Proc Natl Acad Sci U S A; 2012 Feb; 109(9):3213-9. PubMed ID: 22315428
[TBL] [Abstract][Full Text] [Related]
25. Levodopa gains psychostimulant-like properties after nigral dopaminergic loss.
Engeln M; Fasano S; Ahmed SH; Cador M; Baekelandt V; Bezard E; Fernagut PO
Ann Neurol; 2013 Jul; 74(1):140-4. PubMed ID: 23494678
[TBL] [Abstract][Full Text] [Related]
26. AAV.shRNA-mediated downregulation of ROCK2 attenuates degeneration of dopaminergic neurons in toxin-induced models of Parkinson's disease in vitro and in vivo.
Saal KA; Koch JC; Tatenhorst L; Szegő EM; Ribas VT; Michel U; Bähr M; Tönges L; Lingor P
Neurobiol Dis; 2015 Jan; 73():150-62. PubMed ID: 25283984
[TBL] [Abstract][Full Text] [Related]
27. Targeting of the class II transactivator attenuates inflammation and neurodegeneration in an alpha-synuclein model of Parkinson's disease.
Williams GP; Schonhoff AM; Jurkuvenaite A; Thome AD; Standaert DG; Harms AS
J Neuroinflammation; 2018 Aug; 15(1):244. PubMed ID: 30165873
[TBL] [Abstract][Full Text] [Related]
28. α-synuclein aggregation reduces nigral myocyte enhancer factor-2D in idiopathic and experimental Parkinson's disease.
Chu Y; Mickiewicz AL; Kordower JH
Neurobiol Dis; 2011 Jan; 41(1):71-82. PubMed ID: 20816781
[TBL] [Abstract][Full Text] [Related]
29. Overexpression of Parkinson's disease-associated alpha-synucleinA53T by recombinant adeno-associated virus in mice does not increase the vulnerability of dopaminergic neurons to MPTP.
Dong Z; Ferger B; Feldon J; Büeler H
J Neurobiol; 2002 Oct; 53(1):1-10. PubMed ID: 12360578
[TBL] [Abstract][Full Text] [Related]
30. New evidences for fractalkine/CX3CL1 involved in substantia nigral microglial activation and behavioral changes in a rat model of Parkinson's disease.
Shan S; Hong-Min T; Yi F; Jun-Peng G; Yue F; Yan-Hong T; Yun-Ke Y; Wen-Wei L; Xiang-Yu W; Jun M; Guo-Hua W; Ya-Ling H; Hua-Wei L; Ding-Fang C
Neurobiol Aging; 2011 Mar; 32(3):443-58. PubMed ID: 19368990
[TBL] [Abstract][Full Text] [Related]
31. Synapsin III deficiency hampers α-synuclein aggregation, striatal synaptic damage and nigral cell loss in an AAV-based mouse model of Parkinson's disease.
Faustini G; Longhena F; Varanita T; Bubacco L; Pizzi M; Missale C; Benfenati F; Björklund A; Spano P; Bellucci A
Acta Neuropathol; 2018 Oct; 136(4):621-639. PubMed ID: 30046897
[TBL] [Abstract][Full Text] [Related]
32. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.
Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB
Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577
[TBL] [Abstract][Full Text] [Related]
33. Aggregation of αSynuclein promotes progressive in vivo neurotoxicity in adult rat dopaminergic neurons.
Taschenberger G; Garrido M; Tereshchenko Y; Bähr M; Zweckstetter M; Kügler S
Acta Neuropathol; 2012 May; 123(5):671-83. PubMed ID: 22167382
[TBL] [Abstract][Full Text] [Related]
34. Early synaptic dysfunction induced by α-synuclein in a rat model of Parkinson's disease.
Phan JA; Stokholm K; Zareba-Paslawska J; Jakobsen S; Vang K; Gjedde A; Landau AM; Romero-Ramos M
Sci Rep; 2017 Jul; 7(1):6363. PubMed ID: 28743955
[TBL] [Abstract][Full Text] [Related]
35. Down-regulation of alpha-synuclein expression can rescue dopaminergic cells from cell death in the substantia nigra of Parkinson's disease rat model.
Hayashita-Kinoh H; Yamada M; Yokota T; Mizuno Y; Mochizuki H
Biochem Biophys Res Commun; 2006 Mar; 341(4):1088-95. PubMed ID: 16460685
[TBL] [Abstract][Full Text] [Related]
36. Long-term polarization of microglia upon α-synuclein overexpression in nonhuman primates.
Barkholt P; Sanchez-Guajardo V; Kirik D; Romero-Ramos M
Neuroscience; 2012 Apr; 208():85-96. PubMed ID: 22342967
[TBL] [Abstract][Full Text] [Related]
37. Efficient in vivo protection of nigral dopaminergic neurons by lentiviral gene transfer of a modified Neurturin construct.
Fjord-Larsen L; Johansen JL; Kusk P; Tornøe J; Grønborg M; Rosenblad C; Wahlberg LU
Exp Neurol; 2005 Sep; 195(1):49-60. PubMed ID: 15919076
[TBL] [Abstract][Full Text] [Related]
38. Selective loss of nigral dopamine neurons induced by overexpression of truncated human alpha-synuclein in mice.
Wakamatsu M; Ishii A; Iwata S; Sakagami J; Ukai Y; Ono M; Kanbe D; Muramatsu S; Kobayashi K; Iwatsubo T; Yoshimoto M
Neurobiol Aging; 2008 Apr; 29(4):574-85. PubMed ID: 17174013
[TBL] [Abstract][Full Text] [Related]
39. Dopamine receptor agonists reverse behavioral abnormalities of alpha-synuclein transgenic mouse, a new model of Parkinson's disease.
Wakamatsu M; Iwata S; Funakoshi T; Yoshimoto M
J Neurosci Res; 2008 Feb; 86(3):640-6. PubMed ID: 17896793
[TBL] [Abstract][Full Text] [Related]
40. Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation.
During MJ; Kaplitt MG; Stern MB; Eidelberg D
Hum Gene Ther; 2001 Aug; 12(12):1589-91. PubMed ID: 11529246
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
